RxDoctor Payments Data

Raul Diaz de Leon Sanchez, MD

Family Medicine · McAllen, TXNPI 1396207718

Payments from drug & device makers

$1,040in general payments, 2019–2025

Across 32 payments — averaging $32.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$334
  • Lilly USA, LLC$194
  • Bayer$189
  • AstraZeneca$145
  • Novo Nordisk$116
  • Amgen$27
  • plus $35 from 2 others

What the payments were for

  • Food & beverage$1,02699%
  • Education$141%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie14$334
Lilly USA, LLC6$194
Bayer4$189
AstraZeneca3$145
Novo Nordisk1$116
Amgen2$27
GSK1$20
Pfizer1$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,040 in reported general payments places this provider in the 60th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$21,082
Medicare patients
46
Services billed
304

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide35$41,401
RybelsusSemaglutide20$35,264
FarxigaDapagliflozin Propanediol28$29,835
JardianceEmpagliflozin17$18,683
Tresiba Flextouch U-200Insulin Degludec13$12,607
Atorvastatin Calcium150$1,844
Lantus SolostarInsulin Glargine,hum.Rec.Anlog12$1,065
Omeprazole66$903
Allopurinol19$698
Albuterol Sulfate HfaAlbuterol Sulfate22$692
Rosuvastatin Calcium30$610
Tamsulosin Hcl52$569
Celecoxib26$504
Lisinopril66$472
Metformin Hcl75$465

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$116$76,66555 claims
AstraZenecaFarxiga$145$29,83528 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 8,760 family medicine providers in Texas.

Other family medicine in McAllen

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →